Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience
2020
Classical Hodgkin lymphoma (cHL) is a malignancy that arises from clonal germinal center B-cells [1]. Despite favorable outcomes in the front-line setting for most patients, 20–30% of patients deve...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
14
References
1
Citations
NaN
KQI